As the field of neuro-oncology makes headway in uncovering the key oncogenic drivers in
pediatric glioma, the role of precision diagnostics and therapies continues to rapidly evolve …

Abstract The Epidermal Growth Factor Receptor (EGFR) has been targeted through the
development of selective tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAb) …

The majority of glioblastomas can be classified into molecular subgroups based on
mutations in the TERT promoter (TERTp) and isocitrate dehydrogenase 1 or 2 (IDH). These …

Background: Glioma stem cells (GSCs) are a key factor in glioblastoma (GBM) development
and treatment resistance. GSCs can be divided into the mesenchymal (MES) and proneural …

Epithelioid glioblastoma is a rare aggressive variant of glioblastoma (GBM) characterized by
a dismal prognosis of about 6 months and frequent leptomeningeal dissemination. A recent …

Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive
treatment strategies. The use of targeted therapy for BRAF V600E mutated malignancies …

Malignant brain tumors are rapidly progressive and often fatal owing to resistance to
therapies and based on their complex biology, heterogeneity, and isolation from systemic …

BRAF V600 mutations are being identified in patients with primary brain tumors more often
as molecular testing becomes widely available. Targeted treatment with BRAF inhibitors has …

Abstract Purpose of Review Over the last years, our understanding of the molecular biology
of pediatric brain tumors has vastly improved. This has led to more narrowly defined …

Novel therapeutic targets in malignant glioma patients are urgently needed. Point mutations
of the v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene occur predominantly in …